Last updated: 2026-10-12 21:46:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Vogenx Inc. (VOGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17,33, with a market capitalization of $260,86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12,95 to $38,41. This page covers its latest market performance, valuation, price trends and company information.
$260,86M | |
$18,12 | |
$38,41 | |
$12,95 | |
$17,56 | |
85,72K | |
185,09K | |
-- | |
$38,41 | |
$12,95 | |
-- | |
-- |
Vogenx Inc. (VOGX) is trading at $17,27 in after-hours trading as of 2026-10-12 20:11:00, down 1,65% ($0,29) from the regular-session close of $17,56.
After-hours trading shows how investors are pricing VOGX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Vogenx Inc. (VOGX) moved from $20,06 to $17,33, representing a decline of 13,61% ($2,73).
The stock traded between $14,56 and $24,24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99,39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17,2%
VOGX is currently trading at $17,33, placing it 17,2% of the way from its 52-week low of $12,95 to its 52-week high of $38,41. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vogenx Inc. (VOGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.